Biognosys is excited to announce its further expansion into North America. To complement our expanding Business Development and Scientific teams located in the US, we have opened an office in the hub of pharma and biotech in Cambridge, MA. Stay tuned for our ribbon cutting later this year!

We are at ASMS at booth #306. Biognosys is proud of its extensive scientific presence: highlights include the launch of Spectronaut 16, which has undergone one of its most transformative upgrades to date, and innovative studies performed with Biognosys’ proprietary TrueTarget™ and TrueDiscovery™ proteomics platforms for drug and biomarker discovery.

In this white paper, you can learn about the key reasons oncology drug development fails and how Biognosys’ proteomics platforms can support your oncology research pipeline. We collected case studies on the most groundbreaking research advancements from our scientific collaborations and peer-reviewed publications.

Discover a newly emerging game-changer proteomics approach in this Resyn Biosciences’ webinar featuring our Principal Scientist! Learn more about our immunopeptidome profiling service to robustly identify immunopeptides from low amounts of cultured cells and tissue samples and its application in a recent study on lung cancer.